Abstract
The present industry update covers the period 1–30 June 2013, with information sourced from company press releases, regulatory and patent agencies as well as the scientific literature. A number of takeovers of drug delivery specialty companies by big pharma (Pearl Therapeutics by AstraZeneca, MicroDose Therapeutx by Teva), could be observed indicating that the business model of specialty delivery solutions supplementing the pipelines of classical pharmaceutical entities appears to work. Also, one sees substantial investments from equity investors in companies such as Ocular Therapeutics and Mercator MedSystems, as well as government funds (University of Pennsylvania, Oramed Pharmaceuticals) into drug-delivery start-ups, paving the way from ideas to products. Furthermore, an ever increasing number of solutions from the field of nanomedicine are entering the field of drug delivery, mainly preclinical to date, but steadily emerging towards clinical applications such as those published by the Garvan Institute, Svaya Nanotechnologies, Nanosystems Initiative Munich, University of Bern and others
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call